Epithalon for sale: the listing is the only label there is
Epithalon for sale is a search that returns product pages, and product pages are worth treating as documents rather than as shopfronts, because in this market the listing is doing a job that a package insert would do for anything a pharmacy dispenses. An approved medicine arrives with required fields: strength, form, storage conditions, an identified manufacturer, lot number and expiry, all of them mandatory and all of them checked by someone other than the seller. Nothing here is mandatory. Every field on an Epithalon listing is there because the seller chose to put it there, and every field missing is missing for the same reason.
That inverts how you read a page. On a pharmacy label, the presence of information tells you very little, because it is required. On a research-peptide listing, presence and absence are both signals, and absence is usually the louder one. A seller who publishes a measured fill weight has volunteered a number that can be checked against them. A seller who publishes only a purity percentage has answered the question that costs the least to answer.
Get the compound right before reading anything else, because listings frequently do not. Epithalon is a synthetic tetrapeptide, four residues in the order Ala-Glu-Asp-Gly, catalogued at PubChem CID 219042, formula C14H22N4O9, molecular weight 390.35. FDA and PubChem write Epitalon; sellers write Epithalon; a search for epitalon for sale reaches the same shelf. If a listing describes a seven-residue peptide it has confused this with Selank or Semax, and a listing quoting a molecular weight in the hundreds of thousands is describing something else entirely. One supplier is linked here and we earn a commission on purchases, as our affiliate disclosure explains.
The fields a real listing states
Here is the set worth checking, in the order a careful reader would go through them. Each is a factual claim the seller can be held to, which is the whole point: opinions on a product page are free, and checkable claims are not.
Form. Lyophilised powder in a sealed vial is the honest answer for this compound. A listing offering a ready-mixed solution has done manufacturing steps that a certificate for raw peptide does not cover, and it should say who did them and under what conditions. Quantity. The label figure, in milligrams, and ideally a measured one. Batch or lot number. Printed on the listing, not merely promised on request, and matching the certificate that is linked. Storage. Conditions before opening and after reconstitution, stated separately, because they are different. Testing scope. Not the word tested, but the list of assays actually run on that lot.
Two of those deserve emphasis because they are where thin listings hide. A batch number that appears only after you ask is a batch number that can be chosen after you have paid, which is the mechanism behind most certificate mismatches in this market. And testing scope is where the word tested does the most work in the least honest way: a listing can say independently tested while carrying nothing but an identity check. Our breakdown of what grade and testing scope mean on a listing for a substance sold into IV bags covers the same trick on a compound where the consequences are more immediate.
The comparison table sets the fields against what a complete listing states, what an incomplete one substitutes, and why each one matters more here than it would on a pharmacy shelf.
| Field | What a complete listing states | What a thin listing substitutes | Why it matters here |
|---|---|---|---|
| Form | Lyophilised powder in a sealed vial | Vague product shots, or a premixed solution with no formulator named | A certificate for raw peptide says nothing about a liquid somebody else prepared |
| Quantity | Label figure in mg, with a measured net content behind it | A label figure alone, never assayed | Per-mg price comparisons collapse when one side is measured and the other asserted |
| Batch or lot number | Printed on the page and matching the linked certificate | Available on request, after payment | A lot number chosen after checkout is how certificate mismatches happen |
| Storage | Conditions before opening and after reconstitution, stated separately | Keep cool, or nothing at all | The two conditions differ, and the second is where handling problems start |
| Testing scope | The named assays run on that lot, with limits and results | The words independently tested, with no panel listed | Endotoxin and sterility are the screens most often missing and most relevant here |
| Regulatory statement | Research material, not for human consumption, stated plainly | Wellness framing that implies a medical product | Epitalon has no approval and no lawful compounded route in the United States |
Certificate results are from batch 15-05260628, Kovera Labs report KVR-2026-A36FF4, certified 23 May 2026. Listing details checked on 23 August 2026.
The field that does the most work: measured net content
Net content is the field almost nobody checks and the one that changes what you actually pay, which is a strange combination and the reason this page dwells on it.
Here is the specific case. The listing we link publishes a certificate for batch 15-05260628, tested by Kovera Labs, report KVR-2026-A36FF4, certified 23 May 2026. Net content assays at 9.64 mg in a vial labelled 10 mg. The specification is 10 mg plus or minus 10 percent, so the batch passes. It is nonetheless under its own label by 0.36 mg, which is 3.6 percent.
Think about what it takes for that number to reach a public web page. Somebody assayed the fill, the result came back slightly short, and the document was published with the short number on it rather than quietly replaced by the label figure. That is a small thing and it is not nothing, because the entire premise of buying from this channel is that the seller's documents are the only quality assurance you get. A document that occasionally contains something unflattering is a document that is being produced rather than composed.
It is also the mirror image of what the same vendor's Selank lot did, where the assay came back at 12.29 mg against a 10 mg label and the buyer got more than was advertised. Overfill and underfill are equally informative. What tells you nothing is the far more common listing where the fill was never measured at all, and the milligram figure on the front of the vial is simply an intention. Our look at what a listing states where a label would be, on the peptide most often stocked beside this one runs the same field-by-field reading against a lot that ran over.
The arithmetic that follows is short. The vial is $50.00 list, marked down from $69.99, and $25.00 with the code PEPTIDEDECK. On the label that is $2.50 per milligram. On the 9.64 mg measured, it is $2.59. We publish both because the second is the one you receive, and because a per-milligram comparison across sellers is meaningless if one side is measured and the other is asserted. Quantity tiers of 3, 5 or 10 vials take 3, 5 or 10 percent off the list price separately, free shipping starts at $250, and whether the code combines with the tiers is not documented anywhere we can point you at. Figures checked on the listing on 23 August 2026.
Testing scope is a property of the batch, not of the seller
The most common misreading of a peptide listing is to treat testing as something a company either does or does not do. It is not. Testing is something a particular lot either received or did not, and the same seller can ship one lot with a full panel and another with an identity check.
That is not a hypothetical about this vendor. The same company publishes two certificates each for Selank and Semax, and in both cases the earlier document is materially thinner than the later one. For Epithalon there is a single certificate, batch 15-05260628, and its panel is the fuller kind: purity at 99.312 percent against a stated specification of greater than 98 percent, identity confirmed, an endotoxin safety screen passing against a limit of 0.5 EU/mL or lower, a microbial sterility screen reporting no growth, and heavy metals screened including arsenic, cadmium and mercury.
Which means the correct question to a listing is never has this been tested. It is which lot am I receiving, and what appears on that lot's certificate. If the vial that arrives carries a different lot number from the document on the product page, the document is describing somebody else's powder. That is the failure mode this market produces most often, and it is invisible unless you compare the two numbers when the parcel lands.
Format compounds the point. A sealed lyophilised vial is stable and its testing describes what is inside it. Anything premixed, repackaged or decanted has been through steps that occurred after the assay, and no certificate reaches past those steps. Our piece on the formats a pharmacy would refuse to accept covers what happens to the paperwork when a peptide is sold in anything other than the container it was tested in.
The claims in the copy, and what they rest on
The last thing to read on an Epithalon listing is the marketing paragraph, and the right way to read it is as a separate document from the certificate, because it is one. This compound is sold on longevity. Telomere language appears constantly, and so does the implication, rarely the outright statement, that the substance extends lifespan.
What sits behind those claims is largely Russian-language research from a single group, the same lineage that produced the compound from a pineal extract called epithalamin. Reporting that is fair. Repeating it as established is not, and it has never been reviewed and accepted by a Western regulator. No certificate of analysis speaks to it in either direction: a batch report tells you what is in the vial, not what happens after it leaves.
The regulatory picture underneath the copy is short and worth stating plainly on any page that sells this. Epitalon has no FDA approval. It is not on any part of FDA's 503A bulks list: it was nominated, placed in category 2 under the interim policies while under evaluation, and the nomination was withdrawn, so it sits on no current category list. The agency's stated concern, from its page on bulk drug substances that may present significant safety risks, is a risk of immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities, alongside the statement that it has not identified safety-related information regarding epitalon for the proposed route of administration.
Hold those two findings together, because a listing will only ever show you one. The testing panel on batch 15-05260628 addresses aggregation and impurities, which are manufacturing questions and exactly what laboratory work is for. It does not address, and cannot address, whether the substance does anything good or harmful in a person. A well-documented batch of an unevaluated compound is precisely what this listing is, and describing it that way is the difference between a review and an advertisement.